Sirolimus formulation

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

Reexamination Certificate

active

08053444

ABSTRACT:
The present invention relates to a stable pharmaceutical composition that includes sirolimus. The pharmaceutical composition includes sirolimus in the amorphous form, a fatty acid ester, such as glyceryl behenate, and a pharmaceutically acceptable polymer wherein the fatty acid ester is present at a concentration of less than 10% w/w compared to the total weight of the composition.

REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 2003/0180352 (2003-09-01), Patel et al.
patent: 2003/0211160 (2003-11-01), Guitard et al.
patent: 0868911 (1998-10-01), None
patent: 1092429 (2001-04-01), None
patent: WO2006/039237 (2006-04-01), None
patent: WO2006/094507 (2006-09-01), None
Morissette et al. (Advanced Drug Delivery Reviews, vol. 56, pp. 275-300; 2004).
Vippagunta et al. (Advanced Drug Delivery Reviews, vol. 48, Abstract; 2001).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Sirolimus formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sirolimus formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sirolimus formulation will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4296225

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.